Detection of Small Hepatocellular Carcinoma

Kim, Young Kon; Kim, Chong Soo; Han, Young Min; Park, Gun

doi:10.1097/rli.0b013e3181e943a7

Cited by 50 publications

(5 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hepatocyte-specific gadolinium chelate agents are relatively new and are not currently included in the guideline recommendations. Gadoxetic acid (Gd-EOB-DTPA, Primovist, Bayer) and gadopentetate dimeglumine (Gd-BOPTA, Multihance, Bracco) are two such contrast agents that have been shown to improve diagnosis of HCC, showing diagnostic performance similar to or better than SPIO [67, 68] and comparable to double contrast MRI [69]. …”

Section: Imaging Diagnosismentioning

confidence: 99%

APASL and AASLD Consensus Guidelines on Imaging Diagnosis of Hepatocellular Carcinoma: A Review

Tan

Low

Thng

2011

International Journal of Hepatology

View full text Add to dashboard Cite

Consensus guidelines for radiological diagnosis of hepatocellular carcinoma (HCC) have been drafted by several large international working groups. This article reviews the similarities and differences between the most recent guidelines proposed by the American Association for Study of Liver Diseases and the Asian Pacific Association for the Study of the Liver. Current evidence for the various imaging modalities for diagnosis of HCC and their relevance to the consensus guidelines are reviewed.

show abstract

Section: Imaging Diagnosismentioning

confidence: 99%

APASL and AASLD Consensus Guidelines on Imaging Diagnosis of Hepatocellular Carcinoma: A Review

Tan

Low

Thng

2011

International Journal of Hepatology

View full text Add to dashboard Cite

show abstract

“…Until now, accumulating evidence has demonstrated that gadoxetic acid-enhanced MRI may provide better detection and characterization of HCCs compared with MDCT by permitting simultaneous evaluation of tumor vascularity as well as hepatocellular function [29,65,78,81,82,105,106,107,108,109,110]. Since OATP expression declines during hepatocarcinogenesis, approximately 88-95% of HCCs have low or no OATP8 expression and do not take up gadoxetic acid and therefore show hypointensity on hepatobiliary phase imaging [111,112].…”

Section: Diagnostic Criteriamentioning

confidence: 99%

2014 KLCSG-NCC Korea Practice Guidelines for the Management of Hepatocellular Carcinoma: HCC Diagnostic Algorithm

Lee

Park

Choi

2014

Dig Dis

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is the fifth most commonly occurring cancer in Korea and typically has a poor prognosis with a 5-year survival rate of only 28.6%. Therefore, it is of paramount importance to achieve the earliest possible diagnosis of HCC and to recommend the most up-to-date optimal treatment strategy in order to increase the survival rate of patients who develop this disease. After the establishment of the Korean Liver Cancer Study Group (KLCSG) and the National Cancer Center (NCC), Korea jointly produced for the first time the Clinical Practice Guidelines for HCC in 2003, revised them in 2009, and published the newest revision of the guidelines in 2014, including changes in the diagnostic criteria of HCC and incorporating the most recent medical advances over the past 5 years. In this review, we will address the noninvasive diagnostic criteria and diagnostic algorithm of HCC included in the newly established KLCSG-NCC guidelines in 2014, and review the differences in the criteria for a diagnosis of HCC between the KLCSG-NCC guidelines and the most recent imaging guidelines endorsed by the European Organisation for Research and Treatment of Cancer (EORTC), the Liver Imaging Reporting and Data System (LI-RADS), the Organ Procurement and Transplantation Network (OPTN) system, the Asian Pacific Association for the Study of the Liver (APASL) and the Japan Society of Hepatology (JSH).

show abstract

“…In comparison with CT or to conventional MRI with extracellular contrast agent, MRI with liver-specific gadoxetate disodium has been shown to be a promising diagnostic tool for the detection of colorectal liver metastases 2 or hepatocellular carcinoma (HCC). 3…”

Section: Introductionmentioning

confidence: 99%

Diagnostic Efficacy and Safety of Gadoxetate Disodium vs Gadobenate Dimeglumine in Patients With Known or Suspected Focal Liver Lesions: Results of a Clinical Phase III Study

Zech

Schwenke

Endrikat

2019

Magn Reson�Insights

View full text Add to dashboard Cite

Purpose:The aim of this study is to evaluate the diagnostic efficacy and safety of gadoxetate disodium vs gadobenate dimeglumine in patients with known or suspected focal liver lesions.Methods:This was a prospective, multicenter, double-blind, randomized, inter-individual Phase III study. The primary target—technical efficacy—was already published. Here, secondary efficacy parameters—sensitivity and specificity—and safety in specific patient populations are presented. Patients with suspected or known focal liver lesions scheduled for contrast-enhanced liver magnetic resonance imaging (MRI) were recruited and categorized in 4 a priori specified subgroups: (1) all patients, (2) patients with liver cancer (hepatocellular carcinoma [HCC]), (3) patients with cirrhosis, and (4) patients with HCC + cirrhosis. Dual multi-detector liver computed tomography (CT) served as standard of reference.Results:A total of 295 patients were included. While the overall increase in sensitivity across all 4 patient groups was comparable for gadoxetate disodium (increase from pre- to post-contrast ranging from 6.2% to 9.9%) and gadobenate dimeglumine (ranging from −2.9% to 10.0%), significant differences were seen for some of the subgroups. There was a significantly higher increase in sensitivity for gadoxetate disodium in patients with HCC (7%) and HCC + cirrhosis (12.8%) in comparison with gadobenate dimeglumine. Specificity decreased for both agents: gadoxetate disodium by −2.8% to −6.3% and gadobenate dimeglumine by −3.3% to −8.7%. Gadoxetate showed a significantly lower loss of specificity in all subgroups. Safety was comparable in both groups.Conclusions:Gadoxetate disodium proved to be an effective liver-specific MRI contrast agent. Some distinct advantages over gadobenate dimeglumine were demonstrated in patients with HCC and patients with HCC + liver cirrhosis for sensitivity and specificity in liver lesion detection.

show abstract

Detection of Small Hepatocellular Carcinoma

Cited by 50 publications

References 39 publications

APASL and AASLD Consensus Guidelines on Imaging Diagnosis of Hepatocellular Carcinoma: A Review

APASL and AASLD Consensus Guidelines on Imaging Diagnosis of Hepatocellular Carcinoma: A Review

2014 KLCSG-NCC Korea Practice Guidelines for the Management of Hepatocellular Carcinoma: HCC Diagnostic Algorithm

Diagnostic Efficacy and Safety of Gadoxetate Disodium vs Gadobenate Dimeglumine in Patients With Known or Suspected Focal Liver Lesions: Results of a Clinical Phase III Study

Contact Info

Product

Resources

About